|Articles|March 1, 2006
Bausch & Lomb, Novartis Ophthalmics to promote uveitis treatment
Advertisement
Bausch & Lomb and Novartis Ophthalmics will promote the fluocinolone acetonide intravitreal implant, 0.59 mg (Retisert) in the United States. Bausch & Lomb's patented orphan drug treats chronic noninfectious posterior segment uveitis.
The Novartis retinal sales team will target its network of retinal specialists, in order to supplement the efforts of Bausch & Lomb's pharmaceutical sales representatives. Bausch & Lomb will continue its responsibilities of marketing and product strategy.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
SpyGlass Pharma releases positive data from 2 trials of Bimatoprost Drug Pad-IOL System
2
Retina experts reflect on how OCT transformed patient care
3
AAO 2025: The ASPIRE phase 2B trial of UBX1325 head-to-head against aflibercept
4
Redefining glaucoma care: Where innovation meets clinical insight
5















































.png)


